Update on renewal of Cross Guarantee Agreement

Cathay International Holdings Limited ("Cathay" or the "Company")

Update on renewal of Cross Guarantee Agreement

between Jilin Haizi and Lansen's subsidiaries

Hong Kong, 20 June 2019 - Cathay International Holdings Limited (LSE: CTI.L), an operator and investor in the growing healthcare sector in the People's Republic of China, announces its subsidiary, Lansen Pharmaceutical Holdings Limited (Lansen) (HKEX: 503), has notified its shareholders today that, Lansen have published a circular dated 20 June 2019 in relation to the proposed renewal of the 2016 cross guarantee agreement (subject to the approval of Lansen's independent shareholders) as announced on 3 May 2019. Lansen's extraordinary general meeting will be held on 8 July 2019, at which an ordinary resolution will be proposed for the approval of this transaction by the shareholders of Lansen other than Cathay.

The full text of the Lansen circular and notices can be found at https://www1.hkexnews.hk/listedco/listconews/sehk/2019/0620/ltn20190620768.pdf and will also be made available at the Announcements & Notices section of Lansen's homepage at http://holding.lansen.com.cn/en/newslist.aspx?NodeCode=10002000700050005.

- ENDS -

For further enquiries, please contact:

Cathay International Holdings Limited

Eric Siu (Finance Director)                                                                             Tel: +852 2828 9289

Patrick Sung (Director and Controller)

Consilium Strategic Communications

Mary-Jane Elliott/ Matthew Neal / Lindsey Neville                           Tel: +44 (0) 203 709 5700

About Cathay

Cathay International Holdings Limited (LSE: CTI.L) is a main market listed investment holding company and an operator and investor in the healthcare sector in the People's Republic of China (the "PRC"). The Group aims to leverage on investment opportunities in the growing domestic demand for high quality healthcare products in the PRC and build portfolio companies into market sector leaders with competitive edge. Cathay has already demonstrated a track record of identifying investment opportunities in this area including: Lansen, a PRC specialty pharmaceutical company focused on rheumatology and dermatology; Haizi, a PRC inositol manufacturer; Natural Dailyhealth, a company engaged in production and sales of plant extracts for use as key active ingredients in healthcare products; and Botai, a company engaged in collagen products.

The Group employs approximately 1,500 people across the PRC, including over 20 specialist corporate and business development staff based at the holding company's offices in Hong Kong and Shenzhen. Cathay also has a hotel investment in Shenzhen. For more information please visit the Company's website: http://www.cathay-intl.com.hk.